Montgomery-Åsberg Depression Rating Scale Total Score

Biomarker

Also known as: MADRS total score

Related News

COMPASS Pathways Reports Positive Phase 3 Results for Psilocybin in Treatment-Resistant Depression

Mar 09, 2026

COMPASS Pathways announced positive Phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant improvements across two pivotal trials with durability signals through 26 weeks and a generally well-tolerated safety profile.

Psychedelic Therapies Advance in Depression Trials with Mixed Results

Feb 17, 2026

Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.